Multiple myeloma was once viewed as an incurable diagnosis, but Ameet Patel, MD, of Florida Cancer Specialists & Research ...

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient ...

Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple ...